GD2 car-t cell therapy clinical trial site administration and cell distribution logistics
Ended Awarded Last action
- Contract number
- 75N91020F00020
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,247,433
Award facts
- Contract value 100% obligated
- $1,247,433.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Terminate for Convenience | $0 | |
| Other Administrative Action | $0 | |
| Original award | $1,247,433 |
About this award
This is a delivery order contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The $1,247,433.00 cost-plus-fixed-fee contract is for the administration of a GD2 CAR-T cell therapy clinical trial site and cell distribution logistics. The contract has an ultimate completion date of September 27, 2025. There is no set-aside designation indicated. Leidos Biomedical Research Inc. is an established Federally Funded Research and Development Center (FFRDC) contractor that provides a wide range of biomedical research and support services to federal agencies, with a primary focus on NIH programs. This contract award is a task order issued under Leidos Biomedical Research Inc.'s $6.6 billion single-award Indefinite Delivery Contract with the NCI, highlighting the company's extensive capabilities in supporting critical research and clinical trial activities for the National Cancer Institute.
Quick answers
Who was awarded contract 75N91020F00020?
75N91020F00020 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 28, 2020.
How much is contract 75N91020F00020 worth?
The government has obligated $1,247,433 on 75N91020F00020.
Is contract 75N91020F00020 an order under another contract?
Yes. 75N91020F00020 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91020F00020 competed?
The extent of competition for 75N91020F00020 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award